Chávez LA, Flores NG

Language: Spanish
References: 10
Page: 157-162
PDF size: 100.07 Kb.

ABSTRACT

We treat a group of premature neonates with subcutaneous recombinant human erythropoietin, for prevent anemia of prematurity and erythrocyte transfusions, during six weeks. A dose of 200 Units/kg per day three times a week was used. All patients were given supplemental oral iron therapy at a dose of 6 mg/kg per day.
Mean hematocrit and hemoglobin values was higher in the treatment group. Four neonates required transfusions during the study in the treatment group against eleven in the control group. We conclude that recombinant human erythropoietin is effective in reducing the severity of anemia of prematurity and the need for erythrocyte transfusions.

REFERENCES

1. Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 79 (1): F44-F48.

2. Bechensteen AG, Haga P, Halvorsen S, Whitelaw A, Liestol K, Lindemann R et al. Erythropoietin, protein, and iron supplementation and the prevention of anemia of prematurity. Arch Dis Child 1993; 69 (1): 19-23.

3. Shannon KM, Mentzer WC, Abels RI, Wertz M, Thayer-Moriyama J, Li WY et el. Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: a pilot study. J Pediatr 1992; 120 (4): 586-592.

4. Emmerson AJB, Coles HJ, Stern CMM, Pearson TC. Double blind trial of recombinant human erythropoietin in preterm infants. Arch Dis Child 1993; 68 (3): 291-296.

5. Brown MS, Shapiro H. Effect of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. J Pediatr 1996; 128 (4): 512-517.

6. Rutherford CJ, Schneider TJ, Dempsey Kirn DH, Brugnara C, Goldberg MA. Efficacy of different dosing regimen for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med 1994; 96 (2): 139-145.

7. Shanon KM, Keith III JF, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95 (1): 1-8

8. Meyer MP, Haworth C, Meyer JH, Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996; 129 (2): 258-263.

9. Shanon KM, Mentzer WC, Abels RI, Freeman P, Newton N, Thompson D et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Peditr 1991; 118 (6): 949-955.

10. Carnielli V, Montini G, Da Riol R, Dall’ Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Peditr 1992; 121 (1): 98-102.